

March 30, 2015

Therapix Biosciences raises NIS 2.2 million at a 34% premium to market price

Further to the management's efforts to raise capital for the company, Therapix announces an agreement with an unrelated private investor for a private placement of NIS 2.2 million for 4,400,000 of the Company's shares, at NIS 0.5 per share. The investment will give the investor approx. 18.87% of Therapix's share capital (approx. 13.16% on a fully-diluted basis). The capital raise was at a share price that is approx. 34% higher than recent closing price of Therapix's shares. The closing of the agreement is subject to the fulfillment of several conditions which are to be met within 45 days, including receipt of the approval of the Tel Aviv Stock Exchange Ltd. (TASE) for the registration of the shares for trade.

Dr. Asher Shmulewitz, the Company's Chairman, stated that the investment agreement constitutes a vote of confidence in the Company's strategy and management, will reinforce the Company's financial soundness and shall allow it to continue to expand and focus on its activity in the field of medical cannabis. "The collaboration with our new investors is expected to increase interest in Therapix and to contribute to the advancement and expansion of our investments in the world of medical cannabis".

About Therapix

Therapix, is a biopharmaceutical company focused on seeking, identifying and investing in promising technologies in the biopharmaceutical field, while placing an emphasis on technologies that are based on a known biological mechanism which has passed the proof-of-concept phase, and which address significant unmet medical needs and involve an investment of up to \$2 million for achieving a material milestone.

The Company focuses on the creation of a portfolio of technologies and assets in two fields. The first is the field of treatments based on cannabinoids (active compounds in the cannabis plant) and the second is the field of immunotherapy, with the Anti-CD3 antibody.
